Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

diphtheria toxin fragment-interleukin-2 fusion protein E7777

A cytotoxic recombinant fusion protein consisting of the human cytokine interleukin-2 (IL-2) fused to diphtheria toxin fragments A and B, containing both the catalytic and translocation domains, with potential antineoplastic activity. Upon administration, the IL-2 moiety of diphtheria toxin fragment-IL-2 fusion protein E7777 binds to IL-2 receptors. After internalization by IL-2 receptor-expressing cells via endocytosis, the agent is proteolytically cleaved. This releases the catalytic domain of the toxin moiety, which catalyzes the transfer of the ADP-ribose moiety of NAD to a diphthamide residue of elongation factor 2 (EF-2). This covalent modification inactivates EF-2 and disrupts polypeptide chain elongation, resulting in an inhibition of translation and cell death. E7777 has the same amino acid sequence as denileukin diftitox (DD), but has an increased purity profile and an increased percentage of monomeric, active protein, which improves its efficacy.
Code name:E7777
Search NCI's Drug Dictionary